Table 3.
Study adherence and toxicity
| Participant numbers, N = 30 (%) | |
|---|---|
| Adherence | |
| Completed the study according to the protocol | 26 (86.7 %) |
| Did not return for post-treatment study evaluationa | 4 (13.3 %)a |
| Drug compliance (≥5 months, by pill count)b | 25 (96.1 %)b |
| Toxicity | |
| Myalgias | 1 (3.3 %) |
| CPK elevation | 0 |
| Liver transaminase elevation | 0 |
| Otherc | 2c (6.7 %) |
| Lovastatin dose-reduced per study protocold | 1d (3.3 %) |
| Lovastatin discontinued per study protocol | 0 |
a
Two participants were lost to follow-up despite multiple contact attempts. For the two others, one participant was dropped from the study due to inadequate initial breast cytology, and the other did not return for post-treatment evaluation, after having discontinued lovastatin due to unrelated health problems
b
Drug compliance for ≥5 months reported for participants who completed the study (N = 26)
c
Dyspepsia and joint pain in two different participants; resolved spontaneously
d
Dose reduced by 50 % due to myalgias